Samsung Bio Recognized for Crisis Management Capability at All Plants... International Standard for Business Continuity at Plant 3
[Asia Economy Reporter Choi Dae-yeol] Samsung Biologics announced on the 19th that it has obtained the international standard ISO22301 certification for the business continuity management system of its Plant 3 from the British Standards Institution (BSI).
This certification is an international standard set by the International Organization for Standardization (ISO) to minimize business interruptions caused by major incidents. The company previously received this certification from BSI in 2018 for Plants 1 and 2 and some support functions, the first in South Korea.
Plant 3, which was recognized this time, has been in operation since October 2018 and includes the Bio-safety Testing Service lab (BTS) and the small Contract Manufacturing Organization (sCMO). Samsung Biologics Plant 3, with a production capacity of 180,000 liters, is considered the largest biopharmaceutical manufacturing plant in the world based on a single facility.
To obtain this certification, the company formed a task force of 39 members from 32 departments to inspect all possible risks and conduct simulation training. They also established processes to prevent crises in advance and ensure rapid recovery. The company explained that their enterprise-wide response system to infectious diseases such as COVID-19 and real-time communication with clients received high evaluations.
At the award ceremony held at the headquarters in Songdo, Mark Verity, Economic Counselor of the British Embassy, said, "As CMO companies produce medicines directly related to patients' lives, the ability to supply medicines stably is crucial. At a time when the importance of crisis management is emerging worldwide, I congratulate Samsung Biologics on officially certifying its crisis management system by obtaining ISO22301."
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Was This Delicious Treat Enjoyed Only by Koreans?"... The K-Dessert Captivating Japan
- "Iran Considers Usage Fees From Surface to Seabed, Eyes $15 Billion Annual Revenue"
- Fair Trade Commission Fines "Big Five" Couriers Including Coupang and CJ 3 Billion Won for Shifting Safety Accident Liability to Agencies
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Kim Tae-han, CEO of Samsung Biologics, said, "By acquiring ISO22301 for all production facilities including Plants 1, 2, and 3, as well as BTS and sCMO, we have been recognized as a trusted partner by our clients. We will enhance our business competitiveness through quality orders."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.